N/A
Completed N=50
HIV, Buprenorphine, and the Criminal Justice System
Human Immunodeficiency Virus Infection · Acquired Immunodeficiency Syndrome · Opiate Addiction · Drug Dependence
Source: ClinicalTrials.gov NCT01550341 ↗
Enrolled (actual)
50
Serious AEs
0.0%
Results posted
May 2020
Primary outcomePrimary: CD4 Count Absolute — 486.15; 403.92 cells/uL
Summary
The aims of STRIDE were changed as of July, 2014. The revised project, called STRIDE2, has a longitudinal, non-randomized, observational study design. The population under study consists of individuals living with HIV who are dependent on opioids.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY CD4 Count Absolute |
490.25; 492.33 | — |
| PRIMARY CD4 Count Absolute |
490.25; 492.33 | — |
| PRIMARY CD4 Count Absolute |
490.25; 492.33 | — |
| PRIMARY CD4 Percent |
22.14; 27.95 | — |
| PRIMARY CD4 Percent |
22.14; 27.95 | — |
| PRIMARY CD4 Percent |
22.14; 27.95 | — |
| PRIMARY Viral Load |
8122.10; 19425.71 | — |
| PRIMARY Viral Load |
8122.10; 19425.71 | — |
| PRIMARY Viral Load |
8122.10; 19425.71 | — |
| PRIMARY Log Viral Load |
2.40; 1.84 | — |
| PRIMARY Log Viral Load |
2.40; 1.84 | — |
| PRIMARY Log Viral Load |
2.40; 1.84 | — |
| SECONDARY Improved Opioid Treatment Outcomes |
— | — |
| SECONDARY Improved Criminal Justice Outcomes |
— | — |
Eligibility Criteria
Inclusion Criteria
- HIV+
- Age ≥18 yrs
- Meets DSM-IV criteria for opioid dependence
- Has medical entitlements in DC
- Able to provide informed consent
- Able to communicate in English or Spanish
Exclusion Criteria
- Being prescribed an opiate medication for a chronic pain condition or expressing the need to be placed on chronic pain medical conditions for a documented pain condition
- Currently receiving methadone dosing of over 30 mg per day and uninterested in changing to buprenorphine
- AST and ALT >5x the upper limit of normal (AST≥175, ALT≥195)
- Pregnant or unwilling to use contraception (including OCPs, patch, Depo-Provera, condoms, etc.)
- Breastfeeding or unwilling to stop breastfeeding
- Subject is part of another pharmacological research study
- Liver dysfunction (acute hepatitis, liver failure or hepatic dysfunction)
- Suicidal ideation
- Hypersensitivity to buprenorphine
Data sourced from ClinicalTrials.gov (NCT01550341). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.